Shares of Impax Laboratories spiraled down more than 25% today after the company reported that the FDA continues to have concerns with one of its manufacturing facilities. This issue has already held up the potential approval of the company's Parkinson's disease drug, Rytary -- a therapeutic that the company has partially licensed to pharma stalwart GlaxoSmithKline -- which was rejected by the FDA in January. In the following video, health care analyst Max Macaluso sheds light on this story.
If you're seeking companies with huge potential, our new free report "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice" highlights three less-than-luxurious stocks the market is ignoring. Click here to read it now.
The article Down 27%: Impax Labs' Massive Drop originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.